Cocaine-induced erythrocytosis and increase in von Willebrand factor: Evidence for drug-related blood doping and prothrombotic effects

Archives of Internal Medicine

Volumn 159, Issue 16, 1999, Pages 1925-1930

  Siegel, Arthur J ^a,g   Sholar, Michelle B ^a   Mendelson, Jack H ^a,g   Lukas, Scott E ^a,g   Kaufman, Marc J ^a,g   Renshaw, Perry F ^a,g   McDonald, Jane C ^a   Lewandrowski, Kent B ^b,g   Apple, Fred S ^c   Stec, James J ^d   Lipinska, Isabella ^d   Tofler, Geoffrey H ^e   Ridker, Paul M ^f,g  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; CREATININE; FIBRINOGEN; HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I; TROPONIN T; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; FEMALE; FIBRINOLYSIS; HEMATOCRIT; HUMAN; MALE; PRIORITY JOURNAL; SUBSTANCE ABUSE; THROMBOGENESIS; UREA NITROGEN BLOOD LEVEL;

ADULT; BLOOD VISCOSITY; COCAINE-RELATED DISORDERS; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; POLYCYTHEMIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0033552082     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.16.1925     Document Type: Article

References (59)

1. Hollander JE, Todd KH, Green G, et al. Chest pain associated with cocaine: an assessment of prevalence in suburban and urban emergency departments. Ann Emerg Med. 1995;26:671-676.
2. Hollander JE, Hoffman RS, Burstein JL, Shih RD, Thode HC. Cocaine-associated myocardial infarction: mortality and complications. Arch Intern Med. 1995;155:1081-1086.
3. Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation. 1999;99:2737-2741.
4. Brogan WC. Lange RA, Glamann DB, Hillis LD. Recurrent coronary vasoconstriction caused by intranasal cocaine: possible role for metabolites. Ann Intern Med. 1992;116:556-561.
5. Moliterno DJ, Willard JE, Lange RA, et al. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med. 1994;331:454-459.
6. Kaufman MJ, Levin JM, Ross MH, et al. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA. 1998; 278:376-380.
7. Shannon RP, Manders WT, Shen YT. Role of blood doping in the coronary vasoconstrictor response to cocaine. Circulation. 1995;92:96-105.
8. Moliterno DJ, Lange RA, Gerard RD, Willard JE, Lackner C, Hillis LD. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am J Med. 1994;96:492-496.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:223-224.
10. Lukas SE, Sholar M, Lundahl LH, et al. Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology. 1996;125:346-354.
11. Penny W, Weinstein M, Salzman EW, et al. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 1991;83: 1630-1636.
12. Jacob P, Elias-Baker GA, Jones RT, Benowitz NL. Determination of benzoylec-gonine and cocaine in biologic fluids by automated gas chromatography. J Chromatogr. 1987;417:277-286.
13. Musto DF. Opium, cocaine and marijuana in American history. Scientific American. 1991;July:40-47.
14. Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med. 1995;332: 1753-1757.
15. Verebey K, Gold MS. From coca leaves to crack: the effects of dose and routes of administration in abuse liability. Psychiatr Ann. 1988;18:513-520.
16. Spielvogel H, Caceres E, Koubi H. et al. Effects of coca chewing on metabolic and hormonal changes during graded incremental exercise to maximum. J Appl Physiol. 1996;80:643-649.
17. Favier R, Caceres E, Koubi H, et al. Effects of coca chewing on hormonal and metabolic responses during prolonged submaximal exercise. J Appl Physiol. 1996; 80:650-655.
18. Sawka MN, Young AJ, Muza SR, Gonzalez RR, Pandolf KB. Erythrocyte reinfusion and maximal aerobic power. JAMA. 1987;257:1496-1498.
19. Casoni I, Ricci G, Ballarin E, et al. Hematological indices of erythropoietin administration in athletes. Int J Sports Med. 1993;14:307-311.
20. Favier R, Caceres E, Sempore B, et al. Fluid regulatory hormone response to exercise after coca-induced body fluid shifts. J Appl Physiol. 1997;83:376-382.
21. Kaufman MJ, Siegel AJ, Mendelson JH, et al. Cocaine administration induces human splenic constriction and altered hematologic parameters. J Appl Physiol. 1998;85:1877-1883.
22. Laub M, Hvid-Jacobsen K, Hovind P, Kanstrup I, Christensen NJ, Nielsen SL. Spleen emptying and venous hematocrit in humans during exercise. J Appl Physiol. 1993;74:1024-1026.
23. Homler HJ. Nontraumatic splenic hematoma related to cocaine abuse. West Med J. 1995;163:160-162.
24. Novielli KD, Chambers CV. Splenic infarction after cocaine use. Ann Intern Med. 1991;114:251-252.
25. Spielvogel H, Rodriguez A, Sempore B, et al. Body fluid homeostasis and cardiovascular adjustments during submaximal exercise: influence of chewing coca leaves. Eur J Appl Physiol Occup Physiol. 1997;75:400-406.
26. Sawka MN, Joyner MJ, Miles DS, et al. The use of blood doping as an ergogenic aid: American College of Sports Medicine Position Paper. Med Sci Sports Exerc. 1996;28:i-vii.
27. United States Olympic Committee, Drug Control Education, Doping Methods, Peptide and Glycoprotein Hormones. Position statements as of January 18, 1998. Available at: http://www.olympic-usa.org. Accessed June 19, 1998.
28. Cantwell JD, Rose FD. Cocaine and cardiovascular events. Phys Sports Med. 1986; 14:77-82.
29. Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med. 1987;317:781-787.
30. Kerle KK, Nishimura KD. Exertional collapse and sudden death associated with sickle cell trait. Am Fam Phys. 1996;54:237-239.
31. Kaufman MJ, Levin JM, Maas LC, et al. Cocaine decreases relative cerebral blood volume in humans: a dynamic susceptibility contrast magnetic resonance imaging study. Psychopharmacology. 1998;138:76-81.
32. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991;66: 351-355.
33. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809-813.
34. Spom LA, Warder V, Wagner DD. Inducible secretion of large, biological potent vWF multimers. Cell. 1996;46:185.
35. Furlan M, Robles R, Lammie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
36. Rinder HM, Ault KA, Jatlow PI, Kosten TR, Smith BR. Platelet alpha-granule release in cocaine users. Circulation. 1994;90:1162-1167.
37. Heesch CM, Negus BH, Steiner M, et al. Effects of in vivo cocaine administration on human platelet aggregation. Am J Cardiol. 1996;78:237-239.
38. Handin RI. Bleeding and thrombosis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill; 1998;60:339-345.
39. Sholar MB, Mendelson JH, Mello NK, et al. Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. J Clin Endocrinol Metab. 1998;83:966-968.
40. Wilbert-Lampen U, Seliger C, Zilker T, Arendt RM. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine. Circulation. 1998;98:385-390.
41. Arai M, Yorifuji M, Ikematsu S, et al. Influences of strenuous exercise (triathlon) on blood coagulation and fibrinolytic system. Thromb Res. 1990;57:465-471.
42. Boman K, Hellsten G, Bruce A, Hallmans G, Nilsson TK. Endurance physical activity, diet and fibrinolysis. Atherosclerosis. 1994;106:65-74.
43. Eliasson M, Asplund K, Evrin P. Regular leisure time physical activity predicts high activity of tissue plasminogen activator: The Northern Sweden MONICA Study. Am J Epidemiol. 1996;25:1182-1188.
44. Green D, Ruth KJ, Folsom AR, Kiang L. Hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb. 1994;14:686-693.
45. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
46. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Haemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb. 1997;17:3321 -3325.
47. Rosito GBA, Tofler GH. Hemostatic factors as triggers of cardiovascular events. Cardiol Clin. 1997;14:239-250.
48. Baum H, Braun S, Gerhardt W, et al. Multicenter evaluation of a second-generation assay for cardiac troponin T. Clin Chem. 1997;43:1977-1884.
49. Apple FS, Falahati A, Paulsen PR, et al. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem. 1997; 43:2047-2051.
50. Tucker JF, Collins RA, Anderson AJ, et al. Early diagnosis efficiency of cardiac troponin I and troponin T for acute myocardial infarction. Acad Emerg Med. 1997; 4:13-21.
51. Antman EM, Tanasijevic MJ, Thompson B. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
52. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997;337:1648-1653.
53. Polanczyk CA, Lee TH, Cook EF, et al. Troponin I is predictor of cardiac events in acute chest pain patients. J Am Coll Cardiol. 1998;32:8-14.
54. Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J. 1998;135:245-252.
55. McLaurin M, Apple FS, Henry TD, et al. Cardiac troponin I and T concentrations in patients with cocaine-associated chest pain. Ann Clin Biochem. 1996;33:183-186.
56. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation. 1998;98:294-299.
57. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287-289.
58. Hollander J. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267-1272.
59. Mendelson JH, Sholar M, Mello N, Teoh SK, Sholar JW. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsycho-pharmacology. 1998;18:263-271.